Protocol Ledger

NCT04534842 · Phase II · COMPLETED

Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria

Interventional Phase II clinical trial protocol NCT04534842 sponsored by Synlogic in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-25 Enrollment: 20 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04534842
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04534842
Protocol FieldVerified Registry Value
NCT IdentifierNCT04534842
Consolidated Lead SponsorSynlogic
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment20 participants (ACTUAL)
Registered Start Date2020-08-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI